Table 2. Five-year event-free and... | American Society of Hematology

Table 2.

Five-year event-free and overall survival of patients treated in the protocol: CHVP vs HDT

Parameter	Total no. of patients	Event-free survival, %	P	Overall survival, %	P
CHVP	80	48	.050	84	.49
HDT	86	60		78
Age			.28		.060
40 y and younger	23	58		73
Greater than 40 y	143	52		85
ECOG status			.13		.11
0-1	156	56		80
2 or greater	10	75		100
Lymph node areas			.037		.19
4	83	61		84
More than 4	73	45		78
LDH			.19		.09
Normal	110	62		85
Normal or higher	56	51		72
Hb level			.38		.41
Less than 12	48	50		79
12 or greater	118	66		85
Stage			.92		.82
I-II	10	53		75
III-IV	156	60		81
FLIPI			.047		.11
Good	37	67		92
Intermediate	79	64		76
Poor	50	37		75
Good + intermediate	116	56	.025	78	.055
FLIPI
Good + intermediate	116		.30		.14
CHVP	56	50		87
HDT	60	58		77
Poor	50		.018		.15
CHVP	24	20		73
HDT	26	67		82
HDT, purged grafts	61		.019		.014
CD34⁺ selection	53	69		84
B-ceil depletion	8	27		42

Parameter	Total no. of patients	Event-free survival, %	P	Overall survival, %	P
CHVP	80	48	.050	84	.49
HDT	86	60		78
Age			.28		.060
40 y and younger	23	58		73
Greater than 40 y	143	52		85
ECOG status			.13		.11
0-1	156	56		80
2 or greater	10	75		100
Lymph node areas			.037		.19
4	83	61		84
More than 4	73	45		78
LDH			.19		.09
Normal	110	62		85
Normal or higher	56	51		72
Hb level			.38		.41
Less than 12	48	50		79
12 or greater	118	66		85
Stage			.92		.82
I-II	10	53		75
III-IV	156	60		81
FLIPI			.047		.11
Good	37	67		92
Intermediate	79	64		76
Poor	50	37		75
Good + intermediate	116	56	.025	78	.055
FLIPI
Good + intermediate	116		.30		.14
CHVP	56	50		87
HDT	60	58		77
Poor	50		.018		.15
CHVP	24	20		73
HDT	26	67		82
HDT, purged grafts	61		.019		.014
CD34⁺ selection	53	69		84
B-ceil depletion	8	27		42

CHVP indicates cyclophosphmide, doxorubicine, vepesise, prednisone; HDT, high-dose therapy; and FLIPI, Follicular Lymphoma Prognostic Index.